Influence of polymers on the bioavailability of microencapsulated celecoxib

Journal of Microencapsulation

Volumn 24, Issue 7, 2007, Pages 621-633

  Homar, Miha ^a,b   Ubrich, Nathalie ^c   El Ghazouani, Fatima ^c   Kristl, Julijana ^b   Kerč, Janez ^a   Maincent, Philippe ^c  

^a Lek dd   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

^c INSERM   (France)

Author keywords

Celecoxib; In vitro release; Microparticles; Oral bioavailability

Indexed keywords

CELECOXIB; CELLULOSE ACETATE; COPOLYMER; ETHYL CELLULOSE; EUDRAGIT; EUDRAGIT RS; LACTOSE; METHACRYLIC ACID DERIVATIVE; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIC ACID; POLYMER;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; VISCOSITY; WETTABILITY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; CYCLOOXYGENASE INHIBITORS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; LACTOSE; MALE; PARTICLE SIZE; POLYMERS; PYRAZOLES; RABBITS; SULFONAMIDES;

EID: 34548322706     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.1080/09637480701497360     Document Type: Article

References (35)

1. Allemann, E., Leroux, J. and Gurny, R. (1998) Polymeric nano-and microparticles for the oral delivery of peptides and peptidomimetics. Advanced Drug Delivery Reviews, 2, pp. 171-189.
2. Ayalasomayajula, SP and Kompella, UB (2005) Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. European Journal of Pharmacology, 2, pp. 191-198.
3. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, MB, Hawkey, CJ, Hochberg, MC, Kvien, TK and Schnitzer, TJ (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. The New England Journal of Medicine, 343, pp. 1520-1528.
4. De Jaeghere, F., Allemann, E., Cerny, R., Galli, B., Steulet, AF, Muller, I., Schutz, H., Doelker, E. and Gurny, R. (2001) pH-dependent dissolving nano- and microparticles for improved peroral delivery of a highly lipophilic compound in dogs. AAPS PharmSciences, 3, p. E8.
5. Dunne, M., Corrigan, OI and Ramtoola, Z. (2000) Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials, 16, pp. 1659-1668.
6. Fitzgerald, JF and Corrigan, OI (1996) Investigation of the mechanisms governing the release of levamisole from poly-lactide-co-glycolide delivery systems. Journal of Controlled Release, 2, pp. 125-132.
7. Garti, N., Avrahami, M. and Aserin, A. (2006) Improved solubilization of Celecoxib in U-type nonionic microemulsions and their structural transitions with progressive aqueous dilution. Journal of Colloid and Interface Science, 299, pp. 352-365.
8. Graham, D., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S. and Ray, WA (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested control study. Lancet, 365, pp. 475-481.
9. Gupta, P., Chawla, G. and Bansal, AK (2004) Physical stability and solubility advantage from amorphous celecoxib: The role of thermodynamic quantities and molecular mobility. Molecular Pharmacology, 1, pp. 406-413.
10. Hoffart, V., Lamprecht, A., Maincent, P., Lecompte, T., Vigneron, C. and Ubrich, N. (2006) Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. Journal of Controlled Release, 113, pp. 38-42.
11. Hombreiro-Perez, M., Siepmann, J., Zinutti, C., Lamprecht, A., Ubrich, N., Hoffman, M., Bodmeier, R. and Maincent, P. (2003) Non-degradable microparticles containing a hydrophilic and-or a lipophilic drug preparation, characterization and drug release modeling. Journal of Controlled Release, 88, pp. 413-428.
12. Perez, M Hombreiro, Zinutti, C., Lamprecht, A., Ubrich, N., Astier, A., Hoffman, M., Bodmeier, R. and Maincent, P. (2000) The preparation and evaluation of poly(epsilon-caprolactone) microparticles containing both a lipophilic and a hydrophilic drug. Journal of Controlled Release, 65, pp. 429-438.
13. Jeffery, H., Davis, SS and O'Hagan, DT (1993) The preparation and characterization of poly (lactide-co-glycolide) microparticles. II. The entrapment of model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharmaceutical Research, 10, pp. 362-368.
14. Jeong, JC, Lee, J. and Cho, K. (2003) Effects of crystalline microstructure on drug release behavior of poly(epsilon-caprolactone) microspheres. Journal of Controlled Release, 92, pp. 249-258.
15. Jiao, Y., Ubrich, N., Hoffart, V., Marchand-Arvier, M., Vigneron, C., Hoffman, M. and Maincent, P. (2002) Anticoagulant activity of heparin following oral administration of heparin-loaded microparticles in rabbits. Journal of Pharmaceutical Sciences, 91, pp. 760-768.
16. Lee, EJ, Lee, SW, Choi, HG and Kim, CK (2001) Bioavailability of cyclosporin A dispersed in sodium lauryl sulfate-dextrin based solid microspheres. International Journal of Pharmaceutics, 218, pp. 125-131.
17. Luan, X. and Bodmeier, R. (2006) Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems. Journal of Controlled Release, 110, pp. 266-272.
18. Marounek, M., Vovk, SJ and Skrivanova, V. (1995) Distribution of activity of hydrolytic enzymes in the digestive tract of rabbits. British Journal of Nutrition, 73, pp. 463-469.
19. Mehta, RC, Thanoo, BC and Deluca, PP (1996) Peptide containing microspheres from low molecular mass and hydrophilic poly(,-lactide-co-glycolide). Journal of Controlled Release, 41, pp. 249-257.
20. Mukherjee, D., Nissen, SE and Topol, EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. The Journal of the American Medical Association, 286, pp. 954-959.
21. Nagarsenker, MS and Joshi, MS (2005) Celecoxib-cyclodextrin systems: Characterization and evaluation of in vitro and in vivo advantage. Drug Development and Industrial Pharmacy, 31, pp. 169-178.
22. Paulson, SK, Vaughn, MB, Jessen, SM, Lawal, Y., Gresk, CJ, Yan, B., Maziasz, TJ, Cook, CS and Karim, A. (2001) Pharmacokinetics of celecoxib after oral administration in dogs and humans: Effect of food and site of absorption. The Journal of Pharmacology and Experimental Therapeutics, 297, pp. 638-645.
23. Paulson, SK, Zhang, JY, Jessen, SM, Lawal, Y., Liu, NW, Dudkowski, CM, Wang, YF, Chang, M., Yang, D. and Findlay, JW (2000) Comparison of celecoxib metabolism and excretion in mouse, rabbit, dog, cynomolgus monkey and rhesus monkey. Xenobiotica, 7, pp. 731-744.
24. Sansdrap, P. and Moës, AJ (1993) Influence of manufacturing parameters on the size characteristics and the release profiles of nifedipine from poly(-lactide-co-glycolide). International. Journal of Pharmaceutics, 98, pp. 157-164.
25. Seedher, N. and Bhatia, S. (2003) Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech, 4, p. E33.
26. Sengel, CT, Hascicek, C. and Gonul, N. (2006) Development and in-vitro evaluation of modified release tablets including ethylcellulose microspheres loaded with diltiazem hydrochloride. Journal of Microencapsulation, 23, pp. 135-152.
27. Silverstein, FE, Faich, G., Goldstein, JL, Simon, LS, Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, NM and Stenson, WF (2000) Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. The Journal of the American Medical Association, 284, pp. 1247-1255.
28. Simon, LS, Weaver, AL, Graham, DY, Kivitz, AJ, Lipsky, PE, Hubbard, RC, Isakson, PC, Verburg, KM, Yu, SS and Zhao, WW (1999) Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. The Journal of the American Medical Association, 282, pp. 1921-1928.
29. Subramanian, N., Ray, S., Ghosal, SK, Bhadra, R. and Moulik, SP (2004) Formulation design of self-microemulsifying drug delivery systems for improved oral boavailability of celecoxib. Biological and Pharmaceutical Bulletin, 12, pp. 1993-1999.
30. Thakkar, H., Sharma, RK, Mishra, AK, Chuttani, K. and Murthy, RS (2004) Celecoxib incorporated chitosan microspheres: In vitro and in vivo evaluation. Journal of Drug Targeting, 12, pp. 549-557.
31. Thakkar, H., Sharma, RK, Mishra, AK, Chuttani, K. and Murthy, RR (2005) Albumin microspheres as carriers for the antiarthritic drug celecoxib. AAPS PharmSciTech, 6, pp. E65-E73.
32. Ubrich, N., Schmidt, C., Bodmeier, R., Hoffman, M. and Maincent, P. (2005) Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS or RL nanoparticles. International Journal of Pharmaceutics, 288, pp. 169-175.
33. Wang, J., Wang, BM and Schwendeman, SP (2002) Characterization of the initial burst release of a model peptide from poly(-lactide-co-glycolide) microspheres. Journal of Controlled Release, 82, pp. 289-307.
34. Wong, SM, Kellaway, IW and Murdan, S. (2006) Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles. International Journal of Pharmaceutics, 317, pp. 61-68.
35. Zinutti, C., Kedzierewicz, F., Hoffman, M. and Maincent, P. (1994) Preparation and characterization of ethylcellulose microspheres containing 5-fluorouracil. Journal of Microencapsulation, 11, pp. 555-563.